Kobayashi PharmaceuticalKOBAYASHI PHARMACEUTICAL CO.,LTD.4967東証プライム化学FY ending Dec 2025, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|---|
| Domestic Business | -0.2%5y | 115,97220.6% | 125,98018.1% | 130,49716.9% | 119,90119.4% | 118,06411.8% |
| International Business | +17.0%5y | 29,7393.1% | 39,6768.2% | 42,2957.6% | 45,1812.8% | 46,9941.7% |
| Other | +1.4%5y | 546150.2% | 60187.9% | 66274.5% | 51851.0% | 68331.5% |
| Direct Marketing Business | — | 8,9944.4% | 8,4395.0% | — | — | — |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第108期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第107期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第106期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第105期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第104期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第103期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.